Sanofi pays Regeneron $462M to exit immuno-oncology R&D pact

Sanofi is paying Regeneron $462 million (€404 million) to exit the immuno-oncology pact it formed in 2015. The move gives Sanofi the right to opt in to two bispecific programs but otherwise leaves each company free to operate independently.